<DOC>
	<DOCNO>NCT00944658</DOCNO>
	<brief_summary>Presently , treatment available affect progression disease spine . The proven treatment use drug inhibit tumour necrosis factor alpha ( TNF ) . However , limitation treatment need administer via injection also expensive . Therefore necessary develop new therapeutic agent condition . Apremilast ( study drug ) oral tablet show inhibit TNF production mouse model inflammation . It also use clinical trial asthma psoriasis human good affect tolerability . These study fund Celgene Corporation funding study . This study evaluate effectiveness apremilast AS measured improvement patient ' sign symptom disease change image . Additionally safety tolerability apremilast AS assess . The patient recruit hospital Consultant referral . The patient AS least 2 year symptoms uncontrolled conventional non−steroidal anti−inflammatory drug ibuprofen . Patients randomise either receive apremilast placebo treat period 12 week . They follow 28 day treatment period .</brief_summary>
	<brief_title>Spondylitis Trial Apremilast Better Rheumatic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Written inform consent participate trial Diagnosis ankylose spondylitis define modified New York criterion ( 1984 ) follow : 1. history inflammatory back pain ; 2. limitation motion lumbar spine sagittal frontal plane ; 3. limited chest expansion , relative standard value age sex ; 4. definite radiographic / image evidence sacroiliitis and/or spinal inflammation Patients must daily spinal pain stiffness least 2 week prior randomization . This define score &gt; 1 question # 2 # 5 BASDAI score 2 week prior randomization . Patients receive NSAIDS and/or COX2 inhibitor must stable dos least 2 week prior randomization . Age &gt; 18 year Male female patient , surgically sterile postmenopausal , must use reliable method birth control duration study . Males must agree use barrier contraception 3 month follow end trial . Women childbearing potential , surgically sterile postmenopausal , must negative serum beta HCG . Use DMARDs ( methotrexate , dpenicillamine , sulfasalazine , azathioprine , hydroxychloroquine , gold ) within 8 week randomization . Use systemic corticosteroid within 4 week randomization Use intravenous intraarticular corticosteroid within 4 week randomization Use TNF alpha blocker ( eg , infliximab , adalimumab ) etanercept follow : Compound PK Exclusion period Etanercept T ½ = 102 hr = 4.25 day 4 week Adalimumab T ½ 2 wks ; 5 half live 10 week 10 week Infliximab T ½ 7.79.5 12 week 8 week maintenance dose median infx conc 0.56 mcg/ml Therapy investigational agent within 30 day randomization 5 halflives ( pharmacokinetic pharmacodynamic ) , ever long Known HIV hepatitis B C infection Exclusion tuberculosis ( TB ) History active Mycobacterium tuberculosis infection ( subspecies ) within 3 year prior screen visit . Infections occur &gt; 3 year prior entry must effectively treat . History incompletely treat latent Mycobacterium tuberculosis infection ( indicated positive Purified Protein Derivative [ PPD ] skin test ) Clinically significant abnormality chest xray ( CXR ) mantoux &gt; 5mm ELISPOT positive History rheumatic autoimmune disease ( eg , systemic lupus erythematosus , rheumatoid arthritis , etc . ) Pregnant nursing woman Any condition , investigator 's opinion , place patient undue risk participate study . Contraindication MRI MRI exclusion follow local centre guideline ( Appendix H ) An estimate glomerular filtration rate ( eGFR ) &lt; 60 ml/min ( small risk nephrogenic sclerosing fibrosis gadolinium intravenous contrast ) , patient MRI gadolinium contrast . Claustrophobia Hemoglobin &lt; 9 g/dL White blood cell ( WBC ) count &lt; 3000 /μL ( ≥ 3.0 X 109/L ) ≥ 14,000/μL ( ≥ 20 X 109/L ) Neutrophils &lt; 1500 /μL ( &lt; 1.5 X 109/L ) Platelets &lt; 100,000 /μL ( &lt; 100 X 109/L ) Serum creatinine &gt; 1.5 mg/dL ( &gt; 132.6 μmol/L ) Total bilirubin &gt; 2.0 mg/dL Aspartate transaminase ( AST [ serum glutamic oxaloacetic transaminase , SGOT ] ) alanine transaminase ( ALT [ serum glutamate pyruvic transaminase , SGPT ] ) &gt; 1.5x upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>Imaging</keyword>
</DOC>